Clinicopathological features and outcome of gastrointestinal stromal tumors in an Afro-Caribbean population

Journal of the National Medical Association

Volumn 104, Issue 1-2, 2012, Pages 72-77

  Brady West, Doreen ^a   Blake, Garfield ^b  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b St Vincent and the Grenadines   (Jamaica)

Author keywords

Drugs; Gastrointestinal; Tumors

Indexed keywords

CD34 ANTIGEN; IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL PAIN; ADULT; AFRICAN CARIBBEAN; AGED; ARTICLE; CANCER RISK; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; DIGESTIVE SYSTEM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; HIGH RISK BEHAVIOR; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OBSERVATIONAL STUDY; PATHOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINDLE CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 84861815069     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30122-X     Document Type: Article

References (18)

1. Appleman HD. Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues. Am J Surg Pathol. 1986;10(suppl 1):S83-S99.
2. Golden T, Stout AP. Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues. Surg Gynecol Obstet. 1941;73:784-810.
3. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999;30:1213-1220. (Pubitemid 29480891)
4. Hurlimann J, Gardiol D. Gastrointestinal stromal tumors: an immunohistochemical study of 165 cases. Histopathology. 1991;19:311-320.
5. Newman PL, Wadden C, Fletcher CD. Gastrointestinal stromal tumors: correlation of immunophenotype with clinicopathological features. J Pathol. 1991;164:107-117.
6. Nilsson B, Bumming P, Meis-Kindblom JM, et al. GIST: Incidence, prevalence, clinical course and prognostication in the pre-imatinib mesylate eraa population based study in western Sweden. Cancer. 2005;103(4):821-829.
7. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465. (Pubitemid 34747864)
8. DeMatteo RP, Lewis JJ, Leung D, Muden SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors; recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51-58. (Pubitemid 30043939)
9. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical and molecular genetic study of 1765 cases with long- term follow-up. Am J Surg Pathol. 2005;29:52-68. (Pubitemid 40023952)
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors-review on morphology, molecular pathology, prognosis and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466-1478. (Pubitemid 44520713)
11. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655- 664.
12. Dow N, Giblen G, Sobin LH, Miettinen M. Gastrointestinal stromal tumors-differential diagnosis. Semin Diagn Pathol. 2006;23(2):111-119.
13. Miettinen M, Lasota J. Gastrointestinal stromal tumors- definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1-12. (Pubitemid 32128184)
14. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-113. (Pubitemid 38821818)
15. Appelman HD. Mesenchymal tumors of the gut: historical perspectives, new approaches, new results and does it make any difference. Monogr Pathol. 1990;31:220-246.
16. Pierre JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136(4):383-389. (Pubitemid 32322809)
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480. (Pubitemid 34879334)
18. Antonescu CR, Besmer P, Tianhua G, et al. Acquired resistance to imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-4190. (Pubitemid 40791584)